Valiant Laboratories Limited has formally announced the resignation of its Quality Control Manager, Mr. Bhanudas D. Patil, through an official regulatory filing. The resignation was submitted on April 22, 2026, with immediate effect from the closure of business hours on the same date.

Regulatory Compliance and Filing Details

The company has notified both BSE Limited and National Stock Exchange of India Limited about this senior management personnel change, pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary & Compliance Officer Akshay Gangurde signed the official communication on April 23, 2026.

Management Transition Details

According to the formal resignation letter, Mr. Bhanudas D. Patil cited personal commitments as the reason for stepping down from his position. The resignation represents a significant change in the company's quality control leadership structure, as the QC Manager role is critical for overseeing quality assurance processes and regulatory compliance activities.

Quality Control Department Impact

In his resignation letter, Mr. Patil expressed gratitude for the opportunity provided to continue contributing to the organization after his retirement. He acknowledged the support and cooperation extended by the management and colleagues during his tenure. The Quality Control Manager position holds significant responsibility within pharmaceutical operations, ensuring product quality standards and regulatory compliance.

The company has completed the necessary relieving formalities as indicated in the official documentation. This management change follows standard corporate governance practices, with proper disclosure to stakeholders and regulatory authorities as required under SEBI guidelines.

Valiant Laboratories Limited has disclosed receiving a significant Show-Cause Notice from tax authorities, demanding approximately ₹12.53 crores in Goods and Services Tax (GST) along with applicable interest and penalties. The pharmaceutical company made this disclosure under Regulation 30 of SEBI Listing Regulations on January 15, 2026.

Notice Details and Timeline

The Show-Cause Notice, dated January 14, 2026, was received via email on Wednesday at 15:52 IST from the Office of the Commissioner of CGST & Central Excise (Audit), Raigad, Vashi, Navi Mumbai. The notice was issued under the CGST Act, 2017 and SGST Act, 2017, addressing multiple alleged tax compliance issues.

Key Allegations and Financial Impact

The tax demand encompasses three primary areas of concern, each with substantial financial implications:

Specific Compliance Issues

IPO-Related Tax Credit Dispute

The authorities have challenged the Input Tax Credit claimed on expenses incurred for the Initial Public Offer. The department contends that IPO expenses are attributable to "transaction in securities," which qualifies as an exempt supply. Consequently, the ITC claimed on these expenses, approximately ₹2.85 crores, is deemed ineligible as it was exclusively used for exempted goods supply.

Turnover Discrepancy in Transition Period

The notice addresses a turnover mismatch in FY 2021-22, involving approximately ₹9.31 crores in short payment of GST. This discrepancy arose from differences between the taxable turnover declared in Financial Statements and GSTR-3B returns during the transition period when partnership firm 'Bharat Chemicals' was converted into 'Valiant Laboratories Ltd'.

Corporate Guarantee Tax Liability

The third issue concerns non-payment of GST on a ₹100 crore Corporate Bank Guarantee provided to related party M/s. Valiant Advanced Services Pvt Ltd. The department has valued this service at 2% per annum and demanded GST on it, amounting to approximately ₹36 lakhs.

Regulatory Compliance and Next Steps

The company has fulfilled its disclosure obligations under Regulation 30 read with Clause 8 of Para B of Part A of Schedule III of the Listing Regulations. The intimation has been uploaded on the company's website at www.valiantlabs.in and communicated to both BSE Limited and National Stock Exchange of India Limited. The notice proposes penalties under Sections 50, 74, and 122 of the CGST Act, 2017, in addition to the primary tax demand and applicable interest.